Geron Co. (GERN) Given Consensus Rating of “Hold” by Analysts

Shares of Geron Co. (NASDAQ:GERN) have been given a consensus rating of “Hold” by the six brokerages that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $3.75.

GERN has been the subject of several recent research reports. BidaskClub upgraded shares of Geron from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 11th. Needham & Company LLC reiterated a “hold” rating on shares of Geron in a research note on Friday, November 3rd. Stifel Nicolaus reiterated a “hold” rating and issued a $2.50 target price on shares of Geron in a research note on Friday, November 3rd. Finally, Zacks Investment Research downgraded shares of Geron from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd.

Geron (NASDAQ GERN) opened at $2.25 on Friday. The firm has a market cap of $358.27, a PE ratio of -12.50 and a beta of 2.81. Geron has a 12 month low of $1.74 and a 12 month high of $3.15.

A number of large investors have recently modified their holdings of the stock. Raymond James Financial Services Advisors Inc. grew its stake in Geron by 1.8% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 58,056 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 1,000 shares in the last quarter. Voya Investment Management LLC grew its stake in Geron by 12.0% during the second quarter. Voya Investment Management LLC now owns 79,449 shares of the biopharmaceutical company’s stock valued at $220,000 after acquiring an additional 8,534 shares in the last quarter. Alliancebernstein L.P. grew its stake in Geron by 6.9% during the second quarter. Alliancebernstein L.P. now owns 195,911 shares of the biopharmaceutical company’s stock valued at $543,000 after acquiring an additional 12,600 shares in the last quarter. Wells Fargo & Company MN grew its stake in Geron by 13.7% during the second quarter. Wells Fargo & Company MN now owns 122,838 shares of the biopharmaceutical company’s stock valued at $341,000 after acquiring an additional 14,800 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Geron by 0.9% during the second quarter. Northern Trust Corp now owns 1,866,468 shares of the biopharmaceutical company’s stock valued at $5,170,000 after acquiring an additional 16,561 shares in the last quarter. 39.32% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Geron Co. (GERN) Given Consensus Rating of “Hold” by Analysts” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/10/geron-co-gern-given-consensus-rating-of-hold-by-analysts.html.

About Geron

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply